keytruda
Medicare will cover CAR-T therapies in United States
August 8, 2019Sales and Marketing CAR-T therapies, Cancer, Gilead, Kymriah, Medicare, Novartis, keytruda, pharma
Medicare will cover the cost of Novartis’ and Gilead’s CAR-T therapies Kymriah and Yescarta, the US Centers for Medicare and …
Keytruda/chemo combo recommended for first-line lung cancer via Cancer Drugs Fund
August 8, 2019Sales and Marketing CDF, Cancer, MSD, NHS, NICE, UK, keytruda, lung cancer, pharma
MSD’s Keytruda (pembrolizumab) has secured recommendation from NICE for inclusion on the Cancer Drugs Fund (CDF) in combination with chemotherapy …
MSD’s Keytruda combo hits primary endpoint at Phase 3 in triple-negative breast cancer
July 30, 2019Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma
MSD’s blockbuster anti-PD-L1 immunotherapy Keytruda (pembrolizumab) has impressed in newly released Phase 3 data; the company announced that, when combined …
MSD’s Keytruda snatches up first approval in small cell lung cancer
June 19, 2019Research and Development, Sales and Marketing Cancer, FDA, MSD, US, keytruda, lung cancer, pharma
MSD has revealed that its anti-PD-1 immunotherapy Keytruda (pembrolizumab) has been awarded marketing authorisation from the FDA as a monotherapy …
Longest follow up trial of Merck’s Keytruda sets new standard for five year survival in lung cancer
June 3, 2019Sales and Marketing KEYNOTE, MSD, Merck, keytruda, lung cancer
Nearly a quarter of previously untreated lung cancer patients who took Keytruda (Pembrolizumab) were alive after five years, according to …
Keytruda fails to improve overall survival in advanced triple-negative breast cancer
May 21, 2019Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma, triple-negative breast cancer
MSD has made it known that its cancer immunotherapy Keytruda (pembrolizumab) failed to meet its primary endpoint in a Phase …
MSD’s Keytruda recommended on NHS in Scotland for Stage 3 melanoma
May 14, 2019Manufacturing and Production, Sales and Marketing Cancer, MSD, Scotland, Scottish Medicines Consortium, keytruda, melanoma, pharma
MSD has revealed that Keytruda (pembrolizumab) will be made available to NHS Scotland patients after the Scottish Medicines Consortium (SMC) …
Keytruda/Inlyta combo scores FDA approval in advanced kidney cancer
April 23, 2019Manufacturing and Production, Sales and Marketing FDA, MSD, Pfizer, Sutent, inlyta, keytruda, pharma
MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) has secured another approval from the FDA, this time as a first-line treatment in combination …
FDA expands Keytruda label to include stage 3 and 4 non-small cell lung cancer
April 12, 2019Medical Communications, Research and Development Cancer, MSD, keytruda, lung cancer, non-small cell lung cancer, pharma
MSD has revealed that its anti-PD-1 therapy Keytruda (pembrolizumab) has received expanded indication from the FDA to include the first-line …
China approves Keytruda for non-small cell lung cancer
April 2, 2019Manufacturing and Production China, MSD, Merck and Co, USA, keytruda, lung cancer, pharma
US firm MSD has won approval for Keytruda in China. The cancer immunotherapy has thus become the first PD-1 inhibitor …
MSD’s Keytruda/chemo combo nabs EU approval in first-line metastatic squamous lung cancer
March 15, 2019Medical Communications, Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
MSD’s anti-PD-L1 therapy Keytruda (pembrolizumab) has been awarded marketing authorisation in Europe for the first-line treatment of adult patients with …
Top Ten most popular articles on Pharmafile.com this week
February 22, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease
Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …
Keytruda falls short at Phase 3 in advanced liver cancer
February 20, 2019Research and Development Cancer, MSD, keytruda, liver cancer, pharma
MSD has revealed new Phase 3 data which indicates that its blockbuster immunotherapy Keytruda (pembrolizumab), in combination with best supportive …
MSD’s Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma
February 18, 2019Sales and Marketing Cancer, MSD, Merck Sutent, Pfizer, inlyta, keytruda, oncology, rcc, renal cell carcinoma
Merck & Co’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) significantly extended the lives of those with advanced renal …
Keytruda + Inlyta combo beats Pfizer’s chemotherapy Sutent in renal cell carcinoma
February 12, 2019Manufacturing and Production, Research and Development Cancer, MSD, Pfizer, inlyta, keytruda, pharma, renal cell carcinoma
New data has been revealed on the efficacy of MSD’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib), showing it …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
